<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Advancing Drug Development for the Prevention of Spontaneous Preterm Birth; Public Meeting</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Advancing Drug Development for the Prevention of Spontaneous Preterm Birth; Public Meeting</h1>
    <div class="metadata">Published: 2026-02-05 11:15:43</div>
    <div class="summary">The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Advancing Drug Development for the Prevention of Spontaneous Preterm Birth." The meeting will be convened by Duke University's Robert J. Margolis, MD, Center for Health Policy (Duke-Margolis) and supported by a cooperative agreement with FDA. The meeting is intended to gather industry, family, clinician, researcher, ethicist, professional society, and other stakeholder input on the impact of preterm birth on families and on society, as well as on the ethical, regulatory, and clinical trial considerations surrounding the drug development for the prevention of spontaneous preterm birth.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2023/11/22/2023-25816/advancing-drug-development-for-the-prevention-of-spontaneous-preterm-birth-public-meeting" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2023/11/22/2023-25816/advancing-drug-development-for-the-prevention-of-spontaneous-preterm-birth-public-meeting</a></div>
</body>
</html>
